About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Oncolytic Virus Therapies Market Size, Share, Growth and Forecast to 2031
Oncolytic Virus Therapies Market

Oncolytic Virus Therapies Market Size, Share & Trends Analysis Report By Commercialized Therapies (Imlygic, Oncorine, RIGVIR), By Pipeline Therapies (Phase I, Phase II, Phase III, Phase IV), By Type of Virus (Genetically Engineered Oncolytic Virus, Reovirus (Respiratory Enteric Orphan Virus)), By Application (Solid Tumor, Hematological Malignancies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI3581DR
Last Updated : November 29, 2024
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Oncolytic Virus Therapies Market Introduction
    2. By Commercialized Therapies
      1. Introduction
        1. Commercialized Therapies By Value
      2. Imlygic
        1. By Value
      3. Oncorine
        1. By Value
      4. RIGVIR
        1. By Value
    3. By Pipeline Therapies
      1. Introduction
        1. Pipeline Therapies By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    4. By Type of Virus
      1. Introduction
        1. Type of Virus By Value
      2. Genetically Engineered Oncolytic Virus
        1. By Value
        2. Herpes Simplex Virus (HSV)
          1. Herpes Simplex Virus (HSV) By Value
        3. Adenovirus
          1. Adenovirus By Value
        4. Vaccinia Virus
          1. Vaccinia Virus By Value
        5. Oncolytic Wild-Type Virus
          1. Oncolytic Wild-Type Virus By Value
      3. Reovirus (Respiratory Enteric Orphan Virus)
        1. By Value
        2. Newcastle Disease Virus (NDV)
          1. Newcastle Disease Virus (NDV) By Value
        3. Vesicolar Stomatitis Virus (VSV)
          1. Vesicolar Stomatitis Virus (VSV) By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Solid Tumor
        1. By Value
        2. Breast Cancer
          1. Breast Cancer By Value
        3. Prostate Cancer
          1. Prostate Cancer By Value
        4. Lung Cancer
          1. Lung Cancer By Value
        5. Glioblastoma
          1. Glioblastoma By Value
        6. Melanoma
          1. Melanoma By Value
        7. Other Applications
          1. Other Applications By Value
      3. Hematological Malignancies
        1. By Value
        2. Lymphoma
          1. Lymphoma By Value
        3. Leukemia
          1. Leukemia By Value
        4. Myeloma
          1. Myeloma By Value
    1. Introduction
    2. By Commercialized Therapies
      1. Introduction
        1. Commercialized Therapies By Value
      2. Imlygic
        1. By Value
      3. Oncorine
        1. By Value
      4. RIGVIR
        1. By Value
    3. By Pipeline Therapies
      1. Introduction
        1. Pipeline Therapies By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    4. By Type of Virus
      1. Introduction
        1. Type of Virus By Value
      2. Genetically Engineered Oncolytic Virus
        1. By Value
        2. Herpes Simplex Virus (HSV)
          1. Herpes Simplex Virus (HSV) By Value
        3. Adenovirus
          1. Adenovirus By Value
        4. Vaccinia Virus
          1. Vaccinia Virus By Value
        5. Oncolytic Wild-Type Virus
          1. Oncolytic Wild-Type Virus By Value
      3. Reovirus (Respiratory Enteric Orphan Virus)
        1. By Value
        2. Newcastle Disease Virus (NDV)
          1. Newcastle Disease Virus (NDV) By Value
        3. Vesicolar Stomatitis Virus (VSV)
          1. Vesicolar Stomatitis Virus (VSV) By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Solid Tumor
        1. By Value
        2. Breast Cancer
          1. Breast Cancer By Value
        3. Prostate Cancer
          1. Prostate Cancer By Value
        4. Lung Cancer
          1. Lung Cancer By Value
        5. Glioblastoma
          1. Glioblastoma By Value
        6. Melanoma
          1. Melanoma By Value
        7. Other Applications
          1. Other Applications By Value
      3. Hematological Malignancies
        1. By Value
        2. Lymphoma
          1. Lymphoma By Value
        3. Leukemia
          1. Leukemia By Value
        4. Myeloma
          1. Myeloma By Value
    6. U.S.
      1. By Commercialized Therapies
        1. Introduction
          1. Commercialized Therapies By Value
        2. Imlygic
          1. By Value
        3. Oncorine
          1. By Value
        4. RIGVIR
          1. By Value
      2. By Pipeline Therapies
        1. Introduction
          1. Pipeline Therapies By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      3. By Type of Virus
        1. Introduction
          1. Type of Virus By Value
        2. Genetically Engineered Oncolytic Virus
          1. By Value
          2. Herpes Simplex Virus (HSV)
            1. Herpes Simplex Virus (HSV) By Value
          3. Adenovirus
            1. Adenovirus By Value
          4. Vaccinia Virus
            1. Vaccinia Virus By Value
          5. Oncolytic Wild-Type Virus
            1. Oncolytic Wild-Type Virus By Value
        3. Reovirus (Respiratory Enteric Orphan Virus)
          1. By Value
          2. Newcastle Disease Virus (NDV)
            1. Newcastle Disease Virus (NDV) By Value
          3. Vesicolar Stomatitis Virus (VSV)
            1. Vesicolar Stomatitis Virus (VSV) By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Solid Tumor
          1. By Value
          2. Breast Cancer
            1. Breast Cancer By Value
          3. Prostate Cancer
            1. Prostate Cancer By Value
          4. Lung Cancer
            1. Lung Cancer By Value
          5. Glioblastoma
            1. Glioblastoma By Value
          6. Melanoma
            1. Melanoma By Value
          7. Other Applications
            1. Other Applications By Value
        3. Hematological Malignancies
          1. By Value
          2. Lymphoma
            1. Lymphoma By Value
          3. Leukemia
            1. Leukemia By Value
          4. Myeloma
            1. Myeloma By Value
    7. Canada
    1. Introduction
    2. By Commercialized Therapies
      1. Introduction
        1. Commercialized Therapies By Value
      2. Imlygic
        1. By Value
      3. Oncorine
        1. By Value
      4. RIGVIR
        1. By Value
    3. By Pipeline Therapies
      1. Introduction
        1. Pipeline Therapies By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    4. By Type of Virus
      1. Introduction
        1. Type of Virus By Value
      2. Genetically Engineered Oncolytic Virus
        1. By Value
        2. Herpes Simplex Virus (HSV)
          1. Herpes Simplex Virus (HSV) By Value
        3. Adenovirus
          1. Adenovirus By Value
        4. Vaccinia Virus
          1. Vaccinia Virus By Value
        5. Oncolytic Wild-Type Virus
          1. Oncolytic Wild-Type Virus By Value
      3. Reovirus (Respiratory Enteric Orphan Virus)
        1. By Value
        2. Newcastle Disease Virus (NDV)
          1. Newcastle Disease Virus (NDV) By Value
        3. Vesicolar Stomatitis Virus (VSV)
          1. Vesicolar Stomatitis Virus (VSV) By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Solid Tumor
        1. By Value
        2. Breast Cancer
          1. Breast Cancer By Value
        3. Prostate Cancer
          1. Prostate Cancer By Value
        4. Lung Cancer
          1. Lung Cancer By Value
        5. Glioblastoma
          1. Glioblastoma By Value
        6. Melanoma
          1. Melanoma By Value
        7. Other Applications
          1. Other Applications By Value
      3. Hematological Malignancies
        1. By Value
        2. Lymphoma
          1. Lymphoma By Value
        3. Leukemia
          1. Leukemia By Value
        4. Myeloma
          1. Myeloma By Value
    6. U.K.
      1. By Commercialized Therapies
        1. Introduction
          1. Commercialized Therapies By Value
        2. Imlygic
          1. By Value
        3. Oncorine
          1. By Value
        4. RIGVIR
          1. By Value
      2. By Pipeline Therapies
        1. Introduction
          1. Pipeline Therapies By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      3. By Type of Virus
        1. Introduction
          1. Type of Virus By Value
        2. Genetically Engineered Oncolytic Virus
          1. By Value
          2. Herpes Simplex Virus (HSV)
            1. Herpes Simplex Virus (HSV) By Value
          3. Adenovirus
            1. Adenovirus By Value
          4. Vaccinia Virus
            1. Vaccinia Virus By Value
          5. Oncolytic Wild-Type Virus
            1. Oncolytic Wild-Type Virus By Value
        3. Reovirus (Respiratory Enteric Orphan Virus)
          1. By Value
          2. Newcastle Disease Virus (NDV)
            1. Newcastle Disease Virus (NDV) By Value
          3. Vesicolar Stomatitis Virus (VSV)
            1. Vesicolar Stomatitis Virus (VSV) By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Solid Tumor
          1. By Value
          2. Breast Cancer
            1. Breast Cancer By Value
          3. Prostate Cancer
            1. Prostate Cancer By Value
          4. Lung Cancer
            1. Lung Cancer By Value
          5. Glioblastoma
            1. Glioblastoma By Value
          6. Melanoma
            1. Melanoma By Value
          7. Other Applications
            1. Other Applications By Value
        3. Hematological Malignancies
          1. By Value
          2. Lymphoma
            1. Lymphoma By Value
          3. Leukemia
            1. Leukemia By Value
          4. Myeloma
            1. Myeloma By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Commercialized Therapies
      1. Introduction
        1. Commercialized Therapies By Value
      2. Imlygic
        1. By Value
      3. Oncorine
        1. By Value
      4. RIGVIR
        1. By Value
    3. By Pipeline Therapies
      1. Introduction
        1. Pipeline Therapies By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    4. By Type of Virus
      1. Introduction
        1. Type of Virus By Value
      2. Genetically Engineered Oncolytic Virus
        1. By Value
        2. Herpes Simplex Virus (HSV)
          1. Herpes Simplex Virus (HSV) By Value
        3. Adenovirus
          1. Adenovirus By Value
        4. Vaccinia Virus
          1. Vaccinia Virus By Value
        5. Oncolytic Wild-Type Virus
          1. Oncolytic Wild-Type Virus By Value
      3. Reovirus (Respiratory Enteric Orphan Virus)
        1. By Value
        2. Newcastle Disease Virus (NDV)
          1. Newcastle Disease Virus (NDV) By Value
        3. Vesicolar Stomatitis Virus (VSV)
          1. Vesicolar Stomatitis Virus (VSV) By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Solid Tumor
        1. By Value
        2. Breast Cancer
          1. Breast Cancer By Value
        3. Prostate Cancer
          1. Prostate Cancer By Value
        4. Lung Cancer
          1. Lung Cancer By Value
        5. Glioblastoma
          1. Glioblastoma By Value
        6. Melanoma
          1. Melanoma By Value
        7. Other Applications
          1. Other Applications By Value
      3. Hematological Malignancies
        1. By Value
        2. Lymphoma
          1. Lymphoma By Value
        3. Leukemia
          1. Leukemia By Value
        4. Myeloma
          1. Myeloma By Value
    6. China
      1. By Commercialized Therapies
        1. Introduction
          1. Commercialized Therapies By Value
        2. Imlygic
          1. By Value
        3. Oncorine
          1. By Value
        4. RIGVIR
          1. By Value
      2. By Pipeline Therapies
        1. Introduction
          1. Pipeline Therapies By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      3. By Type of Virus
        1. Introduction
          1. Type of Virus By Value
        2. Genetically Engineered Oncolytic Virus
          1. By Value
          2. Herpes Simplex Virus (HSV)
            1. Herpes Simplex Virus (HSV) By Value
          3. Adenovirus
            1. Adenovirus By Value
          4. Vaccinia Virus
            1. Vaccinia Virus By Value
          5. Oncolytic Wild-Type Virus
            1. Oncolytic Wild-Type Virus By Value
        3. Reovirus (Respiratory Enteric Orphan Virus)
          1. By Value
          2. Newcastle Disease Virus (NDV)
            1. Newcastle Disease Virus (NDV) By Value
          3. Vesicolar Stomatitis Virus (VSV)
            1. Vesicolar Stomatitis Virus (VSV) By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Solid Tumor
          1. By Value
          2. Breast Cancer
            1. Breast Cancer By Value
          3. Prostate Cancer
            1. Prostate Cancer By Value
          4. Lung Cancer
            1. Lung Cancer By Value
          5. Glioblastoma
            1. Glioblastoma By Value
          6. Melanoma
            1. Melanoma By Value
          7. Other Applications
            1. Other Applications By Value
        3. Hematological Malignancies
          1. By Value
          2. Lymphoma
            1. Lymphoma By Value
          3. Leukemia
            1. Leukemia By Value
          4. Myeloma
            1. Myeloma By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Commercialized Therapies
      1. Introduction
        1. Commercialized Therapies By Value
      2. Imlygic
        1. By Value
      3. Oncorine
        1. By Value
      4. RIGVIR
        1. By Value
    3. By Pipeline Therapies
      1. Introduction
        1. Pipeline Therapies By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    4. By Type of Virus
      1. Introduction
        1. Type of Virus By Value
      2. Genetically Engineered Oncolytic Virus
        1. By Value
        2. Herpes Simplex Virus (HSV)
          1. Herpes Simplex Virus (HSV) By Value
        3. Adenovirus
          1. Adenovirus By Value
        4. Vaccinia Virus
          1. Vaccinia Virus By Value
        5. Oncolytic Wild-Type Virus
          1. Oncolytic Wild-Type Virus By Value
      3. Reovirus (Respiratory Enteric Orphan Virus)
        1. By Value
        2. Newcastle Disease Virus (NDV)
          1. Newcastle Disease Virus (NDV) By Value
        3. Vesicolar Stomatitis Virus (VSV)
          1. Vesicolar Stomatitis Virus (VSV) By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Solid Tumor
        1. By Value
        2. Breast Cancer
          1. Breast Cancer By Value
        3. Prostate Cancer
          1. Prostate Cancer By Value
        4. Lung Cancer
          1. Lung Cancer By Value
        5. Glioblastoma
          1. Glioblastoma By Value
        6. Melanoma
          1. Melanoma By Value
        7. Other Applications
          1. Other Applications By Value
      3. Hematological Malignancies
        1. By Value
        2. Lymphoma
          1. Lymphoma By Value
        3. Leukemia
          1. Leukemia By Value
        4. Myeloma
          1. Myeloma By Value
    6. UAE
      1. By Commercialized Therapies
        1. Introduction
          1. Commercialized Therapies By Value
        2. Imlygic
          1. By Value
        3. Oncorine
          1. By Value
        4. RIGVIR
          1. By Value
      2. By Pipeline Therapies
        1. Introduction
          1. Pipeline Therapies By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      3. By Type of Virus
        1. Introduction
          1. Type of Virus By Value
        2. Genetically Engineered Oncolytic Virus
          1. By Value
          2. Herpes Simplex Virus (HSV)
            1. Herpes Simplex Virus (HSV) By Value
          3. Adenovirus
            1. Adenovirus By Value
          4. Vaccinia Virus
            1. Vaccinia Virus By Value
          5. Oncolytic Wild-Type Virus
            1. Oncolytic Wild-Type Virus By Value
        3. Reovirus (Respiratory Enteric Orphan Virus)
          1. By Value
          2. Newcastle Disease Virus (NDV)
            1. Newcastle Disease Virus (NDV) By Value
          3. Vesicolar Stomatitis Virus (VSV)
            1. Vesicolar Stomatitis Virus (VSV) By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Solid Tumor
          1. By Value
          2. Breast Cancer
            1. Breast Cancer By Value
          3. Prostate Cancer
            1. Prostate Cancer By Value
          4. Lung Cancer
            1. Lung Cancer By Value
          5. Glioblastoma
            1. Glioblastoma By Value
          6. Melanoma
            1. Melanoma By Value
          7. Other Applications
            1. Other Applications By Value
        3. Hematological Malignancies
          1. By Value
          2. Lymphoma
            1. Lymphoma By Value
          3. Leukemia
            1. Leukemia By Value
          4. Myeloma
            1. Myeloma By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Commercialized Therapies
      1. Introduction
        1. Commercialized Therapies By Value
      2. Imlygic
        1. By Value
      3. Oncorine
        1. By Value
      4. RIGVIR
        1. By Value
    3. By Pipeline Therapies
      1. Introduction
        1. Pipeline Therapies By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    4. By Type of Virus
      1. Introduction
        1. Type of Virus By Value
      2. Genetically Engineered Oncolytic Virus
        1. By Value
        2. Herpes Simplex Virus (HSV)
          1. Herpes Simplex Virus (HSV) By Value
        3. Adenovirus
          1. Adenovirus By Value
        4. Vaccinia Virus
          1. Vaccinia Virus By Value
        5. Oncolytic Wild-Type Virus
          1. Oncolytic Wild-Type Virus By Value
      3. Reovirus (Respiratory Enteric Orphan Virus)
        1. By Value
        2. Newcastle Disease Virus (NDV)
          1. Newcastle Disease Virus (NDV) By Value
        3. Vesicolar Stomatitis Virus (VSV)
          1. Vesicolar Stomatitis Virus (VSV) By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Solid Tumor
        1. By Value
        2. Breast Cancer
          1. Breast Cancer By Value
        3. Prostate Cancer
          1. Prostate Cancer By Value
        4. Lung Cancer
          1. Lung Cancer By Value
        5. Glioblastoma
          1. Glioblastoma By Value
        6. Melanoma
          1. Melanoma By Value
        7. Other Applications
          1. Other Applications By Value
      3. Hematological Malignancies
        1. By Value
        2. Lymphoma
          1. Lymphoma By Value
        3. Leukemia
          1. Leukemia By Value
        4. Myeloma
          1. Myeloma By Value
    6. Brazil
      1. By Commercialized Therapies
        1. Introduction
          1. Commercialized Therapies By Value
        2. Imlygic
          1. By Value
        3. Oncorine
          1. By Value
        4. RIGVIR
          1. By Value
      2. By Pipeline Therapies
        1. Introduction
          1. Pipeline Therapies By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      3. By Type of Virus
        1. Introduction
          1. Type of Virus By Value
        2. Genetically Engineered Oncolytic Virus
          1. By Value
          2. Herpes Simplex Virus (HSV)
            1. Herpes Simplex Virus (HSV) By Value
          3. Adenovirus
            1. Adenovirus By Value
          4. Vaccinia Virus
            1. Vaccinia Virus By Value
          5. Oncolytic Wild-Type Virus
            1. Oncolytic Wild-Type Virus By Value
        3. Reovirus (Respiratory Enteric Orphan Virus)
          1. By Value
          2. Newcastle Disease Virus (NDV)
            1. Newcastle Disease Virus (NDV) By Value
          3. Vesicolar Stomatitis Virus (VSV)
            1. Vesicolar Stomatitis Virus (VSV) By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Solid Tumor
          1. By Value
          2. Breast Cancer
            1. Breast Cancer By Value
          3. Prostate Cancer
            1. Prostate Cancer By Value
          4. Lung Cancer
            1. Lung Cancer By Value
          5. Glioblastoma
            1. Glioblastoma By Value
          6. Melanoma
            1. Melanoma By Value
          7. Other Applications
            1. Other Applications By Value
        3. Hematological Malignancies
          1. By Value
          2. Lymphoma
            1. Lymphoma By Value
          3. Leukemia
            1. Leukemia By Value
          4. Myeloma
            1. Myeloma By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Oncolytic Virus Therapies Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Amgen Inc
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. DAIICHI SANKYO COMPANY LIMITED
    3. DNAtrix
    4. Genelux
    5. Oncolytics Biotech Inc
    6. PsiOxus Therapeutics
    7. RIGVIR Ltd
    8. Shanghai Sunway Biotech Co. Ltd.
    9. SillaJen Inc
    10. Sorrento Therapeutics Inc
    11. Takara Bio Inc
    12. Transgene SA
    13. VCNBiosciences
    14. ViroCure
    15. Viralytics Ltd.(Merck & Co., Inc.) 
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Bispecific Antibodies Market Size The global bispecific antibodies market size was valued at USD 11.84 billion in 2024 and is expected to grow from USD 17.10 billion in 2025 to USD 323.21 billion by 2033, growing at a CAGR of 44.4% du
Buy Now
Global Report
The global X-Ray Inspection System Market size was valued at USD 734.5 Million in 2022 and is projected to reach USD 1231.3 Million by 2031, registering a CAGR of 6.6% during the forecast period (2023-2031). The rising awareness of the bene
Buy Now
Global Report
Inflight Catering Market Size and Trends The global inflight catering market size was valued at USD 13.62 billion in 2023. It is projected to reach from USD 15.16 billion in 2024 to USD 35.75 billion by 2032, growing at a CAGR of 11.32% during the f
Buy Now
Global Report
Bladder Scanners Market Size The global bladder scanners market size was valued at USD 149.28 million in 2024 and is projected to grow from USD 162.36 million in 2025 to reach USD 270.46 million by 2033, exhibiting a CA
Buy Now
Global Report
Hair Removal Wax Market Size The global hair removal wax market size was valued at USD 14426.26 million in 2024 and is projected to reach from USD 15133.14 million in 2025 to USD 22188.76 million by 2033, growing at a CAGR of 4.9% during t
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.